These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 20357375)

  • 1. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.
    Fadini GP; Boscaro E; Albiero M; Menegazzo L; Frison V; de Kreutzenberg S; Agostini C; Tiengo A; Avogaro A
    Diabetes Care; 2010 Jul; 33(7):1607-9. PubMed ID: 20357375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Sitagliptin on the Coronary Flow Reserve, Circulating Endothelial Progenitor Cells and Stromal Cell-derived Factor-1alpha.
    Morishita T; Uzui H; Ikeda H; Amaya N; Kaseno K; Ishida K; Fukuoka Y; Tada H
    Intern Med; 2019 Oct; 58(19):2773-2781. PubMed ID: 31243210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Oral Dipeptidyl-Peptidase-4 Inhibitor Sitagliptin Increases Circulating Levels Of Stromal-Derived Factor-1 Alpha.
    Papazafiropoulou AK; Papanas N; Trikkalinou A; Fousteris E; Melidonis A
    Exp Clin Endocrinol Diabetes; 2018 Jun; 126(6):367-370. PubMed ID: 28931178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α
    Lovshin JA; Rajasekeran H; Lytvyn Y; Lovblom LE; Khan S; Alemu R; Locke A; Lai V; He H; Hittle L; Wang W; Drucker DJ; Cherney DZI
    Diabetes Care; 2017 Aug; 40(8):1073-1081. PubMed ID: 28550195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34⁺CXCR4⁺ cells in patients with type 2 diabetes.
    Aso Y; Jojima T; Iijima T; Suzuki K; Terasawa T; Fukushima M; Momobayashi A; Hara K; Takebayashi K; Kasai K; Inukai T
    Endocrine; 2015 Dec; 50(3):659-64. PubMed ID: 26209038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells.
    Huang CY; Shih CM; Tsao NW; Lin YW; Huang PH; Wu SC; Lee AW; Kao YT; Chang NC; Nakagami H; Morishita R; Ou KL; Hou WC; Lin CY; Shyu KG; Lin FY
    Br J Pharmacol; 2012 Dec; 167(7):1506-19. PubMed ID: 22788747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
    McCormick LM; Kydd AC; Read PA; Ring LS; Bond SJ; Hoole SP; Dutka DP
    Circ Cardiovasc Imaging; 2014 Mar; 7(2):274-81. PubMed ID: 24503784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes.
    Dei Cas A; Spigoni V; Cito M; Aldigeri R; Ridolfi V; Marchesi E; Marina M; Derlindati E; Aloe R; Bonadonna RC; Zavaroni I
    Cardiovasc Diabetol; 2017 Feb; 16(1):27. PubMed ID: 28231835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin.
    Derosa G; Carbone A; D'Angelo A; Querci F; Fogari E; Cicero AF; Maffioli P
    Intern Med; 2013; 52(19):2179-87. PubMed ID: 24088749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term inhibition of DPP-4 enhances endothelial regeneration after acute arterial injury via enhanced recruitment of circulating progenitor cells.
    Brenner C; Kränkel N; Kühlenthal S; Israel L; Remm F; Fischer C; Herbach N; Speer T; Grabmaier U; Laskowski A; Gross L; Theiss H; Wanke R; Landmesser U; Franz WM
    Int J Cardiol; 2014 Nov; 177(1):266-75. PubMed ID: 25499391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.
    Fujita H; Taniai H; Murayama H; Ohshiro H; Hayashi H; Sato S; Kikuchi N; Komatsu T; Komatsu K; Komatsu K; Narita T; Yamada Y
    Endocr J; 2014; 61(2):159-66. PubMed ID: 24225429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of pharmacokinetic parameters and dipeptidyl peptidase-4 inhibition following single doses of sitagliptin in healthy, young Japanese males.
    Herman GA; Mistry GC; Yi B; Bergman AJ; Wang AQ; Zeng W; Chen L; Snyder K; Ruckle JL; Larson PJ; Davies MJ; Langdon RB; Gottesdiener KM; Wagner JA
    Br J Clin Pharmacol; 2011 Mar; 71(3):429-36. PubMed ID: 21284702
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute effects of sitagliptin on progenitor cells and soluble mediators in newly diagnosed type 2 diabetes.
    Xu M; Zhao X; Zheng M; Deng D; Zhang S; Wang Y; Fang Z; Chen M
    Int J Clin Pharmacol Ther; 2020 Sep; 58(9):491-503. PubMed ID: 32567544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin.
    Gagliardino JJ; Santoro S; Arellano S; Di Girolamo G
    Expert Opin Pharmacother; 2008 Jun; 9(9):1495-507. PubMed ID: 18518780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dipeptidyl Peptidase-4 Inhibitor Decreases Allograft Vasculopathy Via Regulating the Functions of Endothelial Progenitor Cells in Normoglycemic Rats.
    Lin FY; Shih CM; Huang CY; Tsai YT; Loh SH; Li CY; Lin CY; Lin YW; Tsai CS
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1111-1127. PubMed ID: 32623597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracellular Ubiquitin(1-76) and Ubiquitin(1-74) Regulate Cardiac Fibroblast Proliferation.
    Jackson EK; Mi E; Ritov VB; Gillespie DG
    Hypertension; 2018 Oct; 72(4):909-917. PubMed ID: 30354710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
    Herman GA; Bergman A; Stevens C; Kotey P; Yi B; Zhao P; Dietrich B; Golor G; Schrodter A; Keymeulen B; Lasseter KC; Kipnes MS; Snyder K; Hilliard D; Tanen M; Cilissen C; De Smet M; de Lepeleire I; Van Dyck K; Wang AQ; Zeng W; Davies MJ; Tanaka W; Holst JJ; Deacon CF; Gottesdiener KM; Wagner JA
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4612-9. PubMed ID: 16912128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule inhibition of dipeptidyl peptidase-4 enhances bone marrow progenitor cell function and angiogenesis in diabetic wounds.
    Whittam AJ; Maan ZN; Duscher D; Barrera JA; Hu MS; Fischer LH; Khong S; Kwon SH; Wong VW; Walmsley GG; Giacco F; Januszyk M; Brownlee M; Longaker MT; Gurtner GC
    Transl Res; 2019 Mar; 205():51-63. PubMed ID: 30452888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sitagliptin ameliorates renal tubular injury in diabetic kidney disease via STAT3-dependent mitochondrial homeostasis through SDF-1α/CXCR4 pathway.
    Zhang Q; He L; Dong Y; Fei Y; Wen J; Li X; Guan J; Liu F; Zhou T; Li Z; Fan Y; Wang N
    FASEB J; 2020 Jun; 34(6):7500-7519. PubMed ID: 32281218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.